Castleark Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Castleark Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-48,160	Closed	-$4.05M	–	356
2021 Q4	$4.05M	Buy	+48,160	New	+$3.92M	0.15%	146
2021 Q1	–	Sell	-18,945	Closed	-$2.62M	–	365
2020 Q4	$2.62M	Sell	18,945 -64,190	-77%	-$7.61M	0.1%	179
2020 Q3	$6.83M	Sell	83,135 -215	-0.3%	-$17.8K	0.27%	108
2020 Q2	$6.52M	Sell	83,350 -850	-1%	-$56.3K	0.28%	104
2020 Q1	$3.74M	Buy	+84,200	New	+$4.37M	0.22%	123
2019 Q3	–	Sell	-56,995	Closed	-$3.62M	–	376
2019 Q2	$3.62M	Sell	56,995 -190	-0.3%	-$12.1K	0.14%	175
2019 Q1	$3.97M	Buy	+57,185	New	+$3.27M	0.15%	171

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Castleark Management's RARE Position: Q1 2022 in Review

Castleark Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 48,160 shares — an estimated $4.05M sold.

Castleark Management first reported a position in RARE in Q1 2019 and held it in 7 quarters. The position peaked at $6.83M in Q3 2020. 240 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

Castleark Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Castleark Management sold 48,160 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $4.05M.
Castleark Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 7 quarters.
Castleark Management's Ultragenyx Pharmaceutical position peaked at $6.83M in Q3 2020.
240 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Castleark Management's 13F filing for Q1 2022, filed 16 May 2022.